Condition: Metastatic Salivary Gland Carcinoma · Recurrent Salivary Gland Carcinoma · Stage III Major Salivary Gland Cancer AJCC v8 · Sponsor: NRG Oncology
This phase II trial compares the effect of usual treatment of docetaxel chemotherapy plus trastuzumab, to ado-emtansine (T-DM1) in patients with HER2-postive salivary gland cancer that has come back (recurrent), that has spread from where it first started (primary site) to other places in the body, or cannot be removed by surgery (unresectable). This trial is also testing how well trastuzumab deruxtecan works in treating patients with HER2-low recurrent or metastatic salivary gland cancer. Trastuzumab is a form of targeted therapy because it works by attaching itself to specific molecules (receptors) on the surface of cancer cells, known as HER2 receptors. When trastuzumab attaches to HER2 receptors, the signals that tell the cells to grow are blocked and the cancer cell may be marked for destruction by body's immune system. Trastuzumab emtansine contains trastuzumab, linked to a chemotherapy drug called emtansine. Trastuzumab attaches to HER2 positive cancer cells in a targeted way and delivers emtansine to kill them. Trastuzumab deruxtecan is a monoclonal antibody called traztuzumab, linked to a chemotherapy drug called deruxtecan. Trastuzumab is a form of targeted therapy because it attaches to specific molecules (receptors) on the surface of cancer cells, known as HER2 receptors and delivers deruxtecan to kill them. Docetaxel is in a class of medications called taxanes. It stops cancer cells from growing and dividing and may kill them. Trastuzumab emtansine may work bette…
This description comes directly from the study's public registry record.
Contact details are listed per location below or on the registry record.
Always discuss trial participation with your own doctor first.
| University of Alabama at Birmingham Cancer Center | Birmingham, Alabama, United States | Active Not Recruiting |
| City of Hope Comprehensive Cancer Center | Duarte, California, United States | Active Not Recruiting |
| Kaiser Permanente Dublin | Dublin, California, United States | Recruiting |
| Kaiser Permanente-Fremont | Fremont, California, United States | Recruiting |
| Kaiser Permanente Fresno Orchard Plaza | Fresno, California, United States | Recruiting |
| Kaiser Permanente-Fresno | Fresno, California, United States | Recruiting |
| City of Hope at Irvine Lennar | Irvine, California, United States | Active Not Recruiting |
| Kaiser Permanente- Modesto MOB II | Modesto, California, United States | Recruiting |
| Kaiser Permanente-Modesto | Modesto, California, United States | Recruiting |
| Kaiser Permanente-Oakland | Oakland, California, United States | Recruiting |
| Stanford Cancer Institute Palo Alto | Palo Alto, California, United States | Recruiting |
| Kaiser Permanente-Roseville | Roseville, California, United States | Recruiting |
+ 140 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT05408845